Funder
Foundation for the Promotion of Cancer Research in Japan
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference20 articles.
1. O’Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401–412
2. Deininger MW, Hodgson JG, Shah NP et al (2016) Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 127(6):703–712
3. Baccarani M, Deininger MW, Rosti G et al (2013) European leukemia net recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884
4. Clinical Pharmacology and Biopharmaceutics Review(s): Iclusig®(ponatinib tablets). Pharmaceuticals and Medical Devices Agency in Japan. https://www.pmda.go.jp/drugs/2016/P20161021002/index.html
5. Narasimhan NI, Dorer DJ, Davis J et al (2014) Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol 74:341–348
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献